Charles Schwab
TPST icon

Charles Schwab’s Tempest Therapeutics TPST Stock Holding History

Charles Schwab’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-135
Closed -$140K – 3357
2020
Q1 		$140K Buy
135
+35
+35% +$51K ﹤0.01% 3070
2019
Q4 		$132K Hold
100
– – ﹤0.01% 3080
2019
Q3 		$139K Hold
100
– – ﹤0.01% 3077
2019
Q2 		$226K Buy
+100
New +$294K ﹤0.01% 3069
2017
Q2 		– Sell
-19
Closed -$107K – 3137
2017
Q1 		$107K Hold
19
– – ﹤0.01% 3010
2016
Q4 		$87K Sell
19
-2
-10% -$24.9K ﹤0.01% 3051
2016
Q3 		$442K Hold
21
– – ﹤0.01% 2650
2016
Q2 		$321K Buy
21
+8
+62% +$183K ﹤0.01% 2760
2016
Q1 		$369K Hold
13
– – ﹤0.01% 2699
2015
Q4 		$380K Hold
13
– – ﹤0.01% 2765
2015
Q3 		$330K Hold
13
– – ﹤0.01% 2786
2015
Q2 		$1.12M Buy
13
+3
+30% +$275K ﹤0.01% 2373
2015
Q1 		$1.06M Buy
10
+2
+25% +$266K ﹤0.01% 2351
2014
Q4 		$1.06M Hold
8
– – ﹤0.01% 2328
2014
Q3 		$399K Hold
8
– – ﹤0.01% 2669
2014
Q2 		$221K Buy
8
+4
+100% +$94.3K ﹤0.01% 2967
2014
Q1 		$115K Hold
4
– – ﹤0.01% 3027
2013
Q4 		$117K Hold
4
– – ﹤0.01% 3045
2013
Q3 		$128K Hold
4
– – ﹤0.01% 3016
2013
Q2 		$174K Buy
+4
New +$150K ﹤0.01% 2951

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Charles Schwab's TPST Position: Q2 2020 in Review

Charles Schwab sold out of Tempest Therapeutics (TPST) in Q2 2020, closing a stake of 135 shares — an estimated $140K sold.

Charles Schwab first reported a position in TPST in Q2 2013 and held it in 20 quarters. The position peaked at $1.12M in Q2 2015. 51 funds tracked by Wall St. Rank hold TPST as of Q2 2020.

  • Charles Schwab reported no remaining Tempest Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Charles Schwab sold 135 Tempest Therapeutics shares in Q2 2020, an estimated $140K.
  • Charles Schwab first reported a position in Tempest Therapeutics in Q2 2013 and held it in 20 quarters.
  • Charles Schwab's Tempest Therapeutics position peaked at $1.12M in Q2 2015.
  • 51 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2020.

Based on Charles Schwab's 13F filing for Q2 2020, filed 14 Aug 2020.